What is tirzepatide and how does it work?

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist of the GLP-1 and GIP receptors, two incretin hormones that help regulate glucose and appetite. By activating both targets at once, it enhances glucose-dependent insulin secretion, lowers glucagon, slows gastric emptying and modulates appetite. It is a prescription drug; this information is educational and does not replace advice from a healthcare professional.

Is prescription tirzepatide the same as the 'research' kind?

No. Mounjaro and Zepbound are prescription medicines made to pharmaceutical standards and dispensed under medical supervision. Tirzepatide sold as 'research use only' or compounded outside that circuit is not approved by the FDA/EMA for human use, carries no quality assurance and has been the subject of regulatory warnings about impurities, mislabelled concentrations and compounding errors. The safe route always runs through a healthcare professional.

← Guides

Tirzepatide: what it is and how it works

Tirzepatide is one of the most talked-about metabolic molecules, partly because of the results of its clinical programs and partly because of the noise that surrounds it on forums and social media. This guide explains, at an educational level, what tirzepatide is, how its dual mechanism is thought to work, under which brands it is approved and the crucial difference between the prescription medicine and material labelled 'research use only' or compounded on the gray market. It is worth being clear from the outset: tirzepatide is a prescription drug. This guide is not medical advice, it contains no doses or protocols and it does not replace assessment by a healthcare professional. If you are considering treatment, that is a conversation for your doctor.

What tirzepatide is

Tirzepatide is a synthetic 39-amino-acid peptide engineered in the laboratory as the first approved dual agonist of two receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Unlike classic GLP-1 agonists, which act on a single target, tirzepatide was designed to activate both incretin pathways. It also incorporates a fatty-acid moiety that promotes binding to albumin in the blood, extending its half-life and allowing once-weekly dosing. It helps to understand it for what it is: a molecule made under controlled conditions, larger and structurally more complex than other metabolic peptides, whose identity and purity depend entirely on a precise synthesis process. The campus tirzepatide profile lists its full name, synonyms and reference data.

How it works: the two incretins

Incretins are hormones the gut releases when we eat that help regulate glucose and appetite. GLP-1 and GIP are two of them. Earlier treatments in this family activated only the GLP-1 receptor; tirzepatide acts on both receptors at once, which is the idea behind 'dual agonism.' Mechanistically, combined GIP and GLP-1 activation enhances insulin secretion in a glucose-dependent way (that is, when there is sugar to handle), lowers the glucagon signal, slows gastric emptying — which contributes to a sense of fullness — and modulates central appetite pathways in the brain. In head-to-head trials, this dual mechanism was associated with larger effects on glycemic control and body weight than GLP-1 agonism alone. It is useful to remember that 'mechanism' describes how the molecule is believed to act, not a promise of any outcome for a specific person.

Approved brands and clinical programs

Tirzepatide is approved by the US FDA and the European EMA, and it is marketed under two brands depending on the indication: Mounjaro for glycemic control in type 2 diabetes, and Zepbound for chronic weight management in obesity or overweight with weight-related comorbidities. It is the same active ingredient authorized for two distinct medical uses, always by prescription and under medical supervision. That approval was not granted on marketing but on the basis of two large Eli Lilly clinical trial programs: the SURPASS program, focused on type 2 diabetes, and the SURMOUNT program, focused on obesity. At a high level, these programs evaluated the molecule against placebo and, in some cases, against other treatments in the same family, and their results support the approved indications. For the specific figures and the reference studies, the campus profile links the original peer-reviewed publications; this guide does not reproduce percentages so they are not read out of context.

Prescription drug versus gray-market material

This is the most important distinction in the whole guide. Mounjaro and Zepbound are prescription medicines: they are manufactured to pharmaceutical standards, dispensed by prescription, and used within a framework of medical supervision that includes risk assessment, contraindications and follow-up. None of that applies to material sold as 'research' tirzepatide, 'research use only,' or compounded outside that circuit. Surging demand and periodic shortages of the approved product have fed a substantial gray market, and regulators have issued specific warnings about impurities, incorrect salt forms, mislabelled concentrations and adverse events linked to compounding errors. Because tirzepatide is a structurally more complex molecule than single-receptor GLP-1 agonists, a poorly synthesized product may not only be impure: it may have a different balance of activity from the one intended. These products are not approved by the FDA or EMA for human use and carry no quality assurance. The safe and legal route to tirzepatide treatment runs through a healthcare professional and a pharmacy, not through an untraceable vial.

Frequently asked questions

What is tirzepatide and how does it work?: Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist of the GLP-1 and GIP receptors, two incretin hormones that help regulate glucose and appetite. By activating both targets at once, it enhances glucose-dependent insulin secretion, lowers glucagon, slows gastric emptying and modulates appetite. It is a prescription drug; this information is educational and does not replace advice from a healthcare professional.
Under which brands is tirzepatide approved?: It is approved by the FDA and the EMA under two brands of the same active ingredient: Mounjaro, for glycemic control in type 2 diabetes, and Zepbound, for chronic weight management in obesity or overweight with comorbidities. Both require a prescription and supervision. The approval rests on the SURPASS (diabetes) and SURMOUNT (obesity) clinical programs.
Is prescription tirzepatide the same as the 'research' kind?: No. Mounjaro and Zepbound are prescription medicines made to pharmaceutical standards and dispensed under medical supervision. Tirzepatide sold as 'research use only' or compounded outside that circuit is not approved by the FDA/EMA for human use, carries no quality assurance and has been the subject of regulatory warnings about impurities, mislabelled concentrations and compounding errors. The safe route always runs through a healthcare professional.

✓ Last reviewed · 2026-07-24